IRIS Accounts Production v25.1.4.42 08610576 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh086105762024-03-31086105762025-03-31086105762024-04-012025-03-31086105762023-03-31086105762023-04-012024-03-31086105762024-03-3108610576ns15:EnglandWales2024-04-012025-03-3108610576ns14:PoundSterling2024-04-012025-03-3108610576ns10:Director12024-04-012025-03-3108610576ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3108610576ns10:SmallEntities2024-04-012025-03-3108610576ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3108610576ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3108610576ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3108610576ns10:FullAccounts2024-04-012025-03-310861057612024-04-012025-03-3108610576ns10:OrdinaryShareClass12024-04-012025-03-3108610576ns10:Director22024-04-012025-03-3108610576ns10:RegisteredOffice2024-04-012025-03-3108610576ns5:CurrentFinancialInstruments2025-03-3108610576ns5:CurrentFinancialInstruments2024-03-3108610576ns5:ShareCapital2025-03-3108610576ns5:ShareCapital2024-03-3108610576ns5:CapitalRedemptionReserve2025-03-3108610576ns5:CapitalRedemptionReserve2024-03-3108610576ns5:RetainedEarningsAccumulatedLosses2025-03-3108610576ns5:RetainedEarningsAccumulatedLosses2024-03-3108610576ns5:NetGoodwill2024-04-012025-03-3108610576ns5:PlantMachinery2024-04-012025-03-3108610576ns5:NetGoodwill2024-03-3108610576ns5:NetGoodwill2025-03-3108610576ns5:NetGoodwill2024-03-3108610576ns5:PlantMachinery2024-03-3108610576ns5:PlantMachinery2025-03-3108610576ns5:PlantMachinery2024-03-3108610576ns10:OrdinaryShareClass12025-03-31
REGISTERED NUMBER: 08610576 (England and Wales)












Unaudited Financial Statements

for the Year Ended 31 March 2025

for

Cytopath Limited

Cytopath Limited (Registered number: 08610576)






Contents of the Financial Statements
for the Year Ended 31 March 2025




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Cytopath Limited

Company Information
for the Year Ended 31 March 2025







Directors: Miss E J Scurrell
Miss L D Fouracre





Registered office: Zoic House
The Southend
Ledbury
Herefordshire
HR8 2EY





Registered number: 08610576 (England and Wales)





Accountants: Crowthers Chartered Accountants
10 The Southend
Ledbury
Herefordshire
HR8 2EY

Cytopath Limited (Registered number: 08610576)

Statement of Financial Position
31 March 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 67,229 65,403
67,229 65,403

CURRENT ASSETS
Stocks 28,324 17,696
Debtors 6 183,124 172,280
Prepayments and accrued income 14,219 14,138
Cash at bank and in hand 1,451,698 648,883
1,677,365 852,997
CREDITORS
Amounts falling due within one year 7 345,057 202,306
NET CURRENT ASSETS 1,332,308 650,691
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,399,537

716,094

PROVISIONS FOR LIABILITIES (16,807 ) (8,397 )

ACCRUALS AND DEFERRED INCOME (10,525 ) (4,920 )
NET ASSETS 1,372,205 702,777

CAPITAL AND RESERVES
Called up share capital 8 500 500
Capital redemption reserve (451,750 ) (451,750 )
Retained earnings 1,823,455 1,154,027
SHAREHOLDERS' FUNDS 1,372,205 702,777

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Cytopath Limited (Registered number: 08610576)

Statement of Financial Position - continued
31 March 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29 July 2025 and were signed on its behalf by:





Miss E J Scurrell - Director


Cytopath Limited (Registered number: 08610576)

Notes to the Financial Statements
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

Cytopath Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2013, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance

Tangible assets are stated at cost (or deemed cost) less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cytopath Limited (Registered number: 08610576)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

2. ACCOUNTING POLICIES - continued

Financial instruments
Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.
Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


Cytopath Limited (Registered number: 08610576)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2024 - 10 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
Cost
At 1 April 2024
and 31 March 2025 376,000
Amortisation
At 1 April 2024
and 31 March 2025 376,000
Net book value
At 31 March 2025 -
At 31 March 2024 -

Cytopath Limited (Registered number: 08610576)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
Cost
At 1 April 2024 193,382
Additions 24,235
At 31 March 2025 217,617
Depreciation
At 1 April 2024 127,979
Charge for year 22,409
At 31 March 2025 150,388
Net book value
At 31 March 2025 67,229
At 31 March 2024 65,403

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 183,124 172,280

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 12,586 12,513
Tax 254,704 120,795
Social security and other taxes 77,767 68,998
345,057 202,306

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
500 Ordinary £1 500 500